ClinicalTrials.gg
CompletedNCT02859350Updated Oct 15, 2018

Safety, Tolerability and Immunogenicity of PfSPZ Vaccine in an Age De-escalation Trial in Equatorial Guinea.

A Phase 1 interventional study of PfSPZ Vaccine and PfSPZ Challenge (for CHMI) in Malaria, sponsored by Sanaria Inc.. Completed at 1 site in Equatorial Guinea. Open to participants aged 6 Months to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-15.

Sponsored by Sanaria Inc. · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
6 Months to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Malaria by Sanaria Inc. — 3 open to participants now, 3 under way, none of them phase 3. Malaria · Sanaria Inc..

Enrollment
7th of 27
135 · median 67
Started
2016
with 3 others
Phase 1
20 of 27
1 open now
Registered
15th of 27
by date

Among the 27 studies in Malaria by Sanaria Inc., this one is the 7th largest by enrollment, is one of 4 that started in 2016, is one of 20 in phase 1, and was the 15th registered.

Malaria

1,185 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

3 of the 27 studies in Malaria by Sanaria Inc. are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 52 Malaria studies recruiting now, 15 (29%) set no upper age limit and 34 (65%) stop at 75 or younger; 38 take children under 18; 32 take healthy volunteers.

This study: 6 Months to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Malaria by Sanaria Inc., or all of them as a file.
02

Study summary

This trial will evaluate the safety, tolerability, and immunogenicity of PfSPZ Vaccine in healthy Equatoguinean adults, adolescents, children and infants who receive doses of 0.9x10\^6, 1.8x10\^6 or 2.7x10\^6 PfSPZ Vaccine via direct venous inoculation (DVI) compared with control groups receiving normal saline (NS) placebo by DVI. In addition, the study will also assess a second PfSPZ-based vaccination approach known as PfSPZ-CVac- the administration of non-irradiated, infectious PfSPZ (PfSPZ Challenge) (1x10\^5 PfSPZ) under anti-malarial chemoprophylaxis (chloroquine) in younger adults ages 18 to 35 years for safety, tolerability, immunogenicity and efficacy against controlled human malaria infection (CHMI).

Read the detailed description

EGSPZV2 is a single center, double-blind, placebo-controlled trial. The study is to take place at the Baney Temporary Research Facility (BTRF) located in Baney City. One hundred and thirty-five healthy male and female; adults, adolescents, children and infant volunteers, aged from 6 months to 65 years who live in the Baney district and Malabo city on Bioko Island will be enrolled based on pre-defined inclusion and exclusion criteria implemented according to international ethical standards.

The trial will consist of seven groups (Group 1a: younger adults, ages 18-35; Group 2: older adults, ages 36-65; Group 3: adolescents, ages 11-17; Group 4: older children, ages 6-10; Group 5: younger children, ages 1-5; Groups 6a/b: infants, ages 6 months - 11 months) of volunteers. Vaccination will begin in Group 1a (younger adults), with three doses of 2.7x10\^6 PfSPZ Vaccine given eight weeks apart by DVI. An eighth group (Group 1b: younger adults, ages 18- 35), will be uniquely immunized with the comparator vaccine PfSPZ Challenge given under chloroquine prophylaxis (PfSPZ-CVac approach), rather than with PfSPZ Vaccine. A single PfSPZ-CVac younger adult group (group 1b) is included to provide a direct comparison with PfSPZ Vaccine (group 1a) for the ability to protect against CHMI. Each of the first two groups (1a and 1b) will have 20 participants receiving either PfSPZ Vaccine or PfSPZ Challenge and 6 participants receiving NS placebo by DVI, with treatment allocation randomized and double-blind. Volunteers in Group 1b will receive vaccinations 8 weeks after the initial vaccination of Group 1a. Volunteers in Group 1 (younger adults) will receive CHMI between 10 and 14 weeks post last vaccination (with a window of +/- 7 days on each side) and will be followed for 8 weeks following CHMI.

Group 2 (older adults) will receive three doses of 2.7x10\^6 PfSPZ Vaccine. Group 2 will consist of 12 participants receiving PfSPZ Vaccine and 4 participants receiving NS placebo by DVI, given eight weeks apart. Group 3, 4, 5 and 6b will each have 12 participants receiving three doses of 1.8x10\^6 PfSPZ Vaccine and 4 participants receiving NS, also given eight weeks apart. Group 6a will consist of 3 volunteers who will receive a single dose of 9.0 x10\^5 PfSPZ Vaccine.

Sequential age groups will be staggered to allow assessment of safety and tolerability before further age de-escalation. To assure safety, vaccinations will start in younger adults and will progress to younger and older age groups using staggered start dates at approximately weekly intervals. Age escalation and initial age de-escalation will take place at the same time, hence Group 2 and 3 will be vaccinated at the same time. Progressively younger age groups will then be immunized. The decision to proceed with each of these steps will be made by the study team after a review of safety data from the previously vaccinated group(s). Three Safety Monitoring Committee (SMC) meetings are scheduled to review data prior to initiating the younger children and infant groups.

03

Conditions studied

  • Malaria

Keywords

  • Plasmodium falciparum
  • PfSPZ Vaccine
  • PfSPZ Challenge (NF54)
  • CHMI
  • Chloroquine
  • Chemoprophylaxis
  • PfSPZ-CVac
04

Who can participate

Ages eligible
6 Months to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males and females, based on clinical and laboratory findings
  • From the age 6 months to 65 years
  • Adults with a (BMI) 18 to 30 Kg/m2; or adolescents, children and infants with Z-score of the selected indicator ([weight-for-height], [(height and BMI) for age]) category within ±2SD as detailed in protocol
  • Long-term (at least one year) or permanent residence in the Baney district or Malabo city
  • Agreement to release medical information and to inform the study doctor concerning for participation in the study
  • Willingness to be attended to by a study clinician and take all necessary medications prescribed during study period
  • Agreement to provide contact information of a third party household member or close friend to study team
  • Agreement not to participate in another clinical trial during the study period
  • Agreement not to donate blood during the study period
  • Able and willing to complete the study visit schedule over the study follow up period, including the hospitalizations required for protocol compliance
  • .Willingness to undergo , (HBV) and (HCV) tests
  • Volunteer (subjects 18 years of age and older) or the parent / guardian signing the (for subjects \<18 years of age) is able to demonstrate their understanding of the study by responding correctly to 10 out of 10 true/false statements (in a maximum of two attempts for those who failed to respond correctly to all true/false statements in the first attempt).
  • Signed written informed consent, in accordance with local practice, provided by adult volunteers, parents or legal representatives and relevant assent for children participants as applicable.
  • Free from malaria parasitemia by blood smear at enrollment and by PCR for group 1
  • Has not been treated with any antimalarial medication for at least two weeks prior to the first immunization.
  • Free from helminth infections (detected by microscopy) at enrollment.
  • Female volunteers aged 9 years and above must be non-pregnant (as demonstrated by a negative urine pregnancy test), and provide consent/assent of their willingness to take protocol-defined measures not to become pregnant during the study and safety follow-up period.

Exclusion criteria

Exclusion Criteria:

  • Previous receipt of an malaria vaccine in the last 5 years
  • Participation in any other clinical study involving investigational medicinal products including investigational malaria drugs within 30 days prior to the onset of the study or during the study period
  • History of arrhythmias or prolonged -interval or other cardiac disease, or abnormalities in (ECG) at screening
  • Positive family history in a 1st or 2nd degree relative for cardiac disease at age \<50 years old
  • A history of psychiatric disease
  • Suffering from any chronic illness including; diabetes mellitus, cancer or /AIDS
  • Any confirmed or suspected or immune-deficient condition, including asplenia
  • History of drug or alcohol abuse interfering with normal social function
  • The use of chronic immunosuppressive drugs or other immune modifying drugs within three months of study onset (inhaled and topical are allowed) and during the study period
  • Any clinically significant deviation from the normal range in biochemistry or hematology blood tests or in urine analysis
  • Positive HIV, virus or virus tests
  • Volunteers who are have risk factors for tuberculosis and/or signs and symptoms of tuberculosis (TB), plus a positive tuberculin skin test (TST).
  • Symptoms, physical signs and laboratory values suggestive of systemic disorders including renal, hepatic, blood, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric, and other conditions which could interfere with the interpretation of the study results or compromise the health of the volunteers
  • Any medical, social condition, or occupational reason that, in the judgment of the investigator, is a to protocol participation or impairs the volunteer's ability to give , increases the risk to the volunteer because of participation in the study, affects the ability of the volunteer to participate in the study or impairs the quality, consistency or interpretation of the study data
  • History of non-febrile seizures or atypical febrile seizures
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    Group 1a (PfSPZ Vaccine)

    18-35 years; n= 20; 3 doses of 2.7x10\^6 PfSPZ Vaccine given eight weeks apart. Volunteers will receive CHMI between 10 and 14 weeks post last vaccination (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.

    Biological: PfSPZ Vaccine · Biological: PfSPZ Challenge (for CHMI)

  • Placebo comparator
    Group 1a (normal saline)

    18-35 years; n=6; 3 doses of normal saline given 8 weeks apart. Volunteers will receive CHMI between 10 and 14 weeks post last dose of NS (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.

    Biological: PfSPZ Challenge (for CHMI) · Other: Normal Saline

  • Experimental
    Group 1b (PfSPZ CVac)

    18-35 years; n=20; 3 doses of 1.0x10\^5 PfSPZ Challenge given every four weeks. Group 1b will start 8 weeks after Group 1a. Volunteers in Group 1b will receive their first immunization after the loading dose of chloroquine has been administered. Volunteers will receive CHMI between 10 and 14 weeks post last vaccination (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.

    Biological: PfSPZ Challenge (for CHMI) · Biological: PfSPZ Challenge (for PfSPZ-CVac)

  • Placebo comparator
    Group 1b (normal saline)

    18-35 years; n=6; 3 doses of normal saline given 4 weeks apart. Group 1b will start 8 weeks after Group 1a. Volunteers will receive CHMI between 10 and 14 weeks post last dose of NS (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.

    Biological: PfSPZ Challenge (for CHMI) · Other: Normal Saline

  • Experimental
    Group 2 (PfSPZ Vaccine)

    36-65 years; n=12; 3 doses of 2.7x10\^6 PfSPZ Vaccine given 8 weeks apart. Group 2 will start 3 weeks after Group 1a.

    Biological: PfSPZ Vaccine

  • Placebo comparator
    Group 2 (normal saline)

    36-65 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 2 will start 3 weeks after Group 1a.

    Other: Normal Saline

  • Experimental
    Group 3 (PfSPZ Vaccine)

    11-17 years; n=12; 3 doses of 1.8x10\^6 PfSPZ Vaccine given 8 weeks apart. Group 3 will start 3 weeks after Group 1a.

    Biological: PfSPZ Vaccine

  • Placebo comparator
    Group 3 (normal saline)

    11-17 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 3 will start 3 weeks after Group 1a.

    Other: Normal Saline

  • Experimental
    Group 4 (PfSPZ Vaccine)

    6-10 years; n=12; 3 doses of 1.8x10\^6 PfSPZ Vaccine given 8 weeks apart. Group 4 will start 4 weeks after Group 1a.

    Biological: PfSPZ Vaccine

  • Placebo comparator
    Group 4 (normal saline)

    6-10 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 4 will start 4 weeks after Group 1a.

    Other: Normal Saline

  • Experimental
    Group 5 (PfSPZ Vaccine)

    1-5 years; n=12; 3 doses of 1.8x10\^6 PfSPZ Vaccine given 8 weeks apart. Group 5 will start 7 weeks after Group 1a.

    Biological: PfSPZ Vaccine

  • Placebo comparator
    Group 5 (normal saline)

    1-5 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 5 will start 7 weeks after Group 1a.

    Other: Normal Saline

  • Experimental
    Group 6a (PfSPZ Vaccine)

    6-11 months; n=3; 1 dose of 9.0x10\^5 PfSPZ Vaccine. Group 6a will start 7 weeks after Group 1a.

    Biological: PfSPZ Vaccine

  • Experimental
    Group 6b (PfSPZ Vaccine)

    6-11 months; n=12; 3 doses of 1.8x10\^6 PfSPZ Vaccine given 8 weeks apart. Group 6b will start 11 weeks after Group 1a.

    Biological: PfSPZ Vaccine

  • Placebo comparator
    Group 6b (normal saline)

    6-11 months; n=4; 3 doses of normal saline given 8 weeks apart. Group 6b will start 11 weeks after Group 1a.

    Other: Normal Saline

Interventions

  • BiologicalPfSPZ Vaccine

    Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)

  • BiologicalPfSPZ Challenge (for CHMI)

    live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge

  • OtherNormal Saline

    0.9% Sodium chloride

  • BiologicalPfSPZ Challenge (for PfSPZ-CVac)

    live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge)

06

What researchers measure

Primary outcomes

  1. Incidence and type of Adverse Events

    Incidence and type of adverse events (including breakthrough infections), vital signs, clinical laboratory assessments, physical examination findings post first immunization onwards. 1. Occurrence of solicited symptoms during a 7-day surveillance period after vaccination (day of vaccination (Vx) and +7 days post vaccination) 2. Occurrence of unsolicited symptoms during a 28-day surveillance period after each vaccination. 3. Occurrence of serious adverse events during the study period. 4. Occurrence of Pf infection of vaccine type detected at any point after the first vaccination (retrospectively determined).

    Time frame: Day of first immunization until one year

Secondary outcomes

  1. Level of Antibodies against Pf proteins in volunteer sera

    1. Antibody titres to pre-erythrocytic stage and erythrocytic stage antigens\[PfCSP, PfLSA-1, PfEBA-175 , PfMSP-1, PfMSP-5, EXP-1\] by ELISA 2. Antibody titres to Pf sporozoites, asexual and sexual erythrocytic stage parasites by IFA. 3. Analysis of antibodies to proteins in the Pf proteome array chip.

    Time frame: Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization

  2. Inhibitory Capacity of Volunteer Sera against in vitro Sporozoite Invasion of Hepatocytes

    Capacity of sera from immunized volunteers to inhibit sporozoite invasion (ISI) of hepatocytes in vitro by ISI assay

    Time frame: Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization

  3. Quantitation of cellular immune responses against Pf proteins in volunteers

    1. Identification of number of vaccine induced PBMCs following Intracellular cytokine staining by flow cytometry after stimulation with PfSPZ or Pf-infected erythrocytes, peptide pools and P. falciparum infected primary human hepatocyte cell lines. 2. Identification of numbers of vaccine induced CD4 and CD8 T cells following FluoroSpot assay after stimulation with PfSPZ or Pf-infected erythrocytes.

    Time frame: Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization

  4. Whole genome expression profiles of volunteer

    Human gene expression profiling focusing on immune response genes in volunteers

    Time frame: Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization

Other outcomes

  1. Time to P. falciparum parasitemia by microscopy over a period of 28 days following CHMI using PfSPZ Challenge by DVI in young adults (aged 18 to 35 years).

    Time frame: Day of CHMI to 28 days later

  2. Proportion of volunteers who develop P. falciparum parasitemia by microscopy over a period of 28 days following CHMI using PfSPZ Challenge by DVI in young adults (aged 18 to 35 years).

    Time frame: Day of CHMI to 28 days later

  3. Time to P. falciparum parasitemia by qPCR over a period of 28 days following CHMI using PfSPZ Challenge by DVI in young adults (aged 18 to 35 years).

    Time frame: Day of CHMI to 28 days later

  4. Proportion of volunteers who develop P. falciparum parasitemia by qPCR over a period of 28 days following CHMI using PfSPZ Challenge by DVI in young adults (aged 18 to 35 years).

    Time frame: Day of CHMI to 28 days later

07

Study locations

1 site
  • La Paz Medical Center
    Malabo, Equatorial Guinea
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Dec 2017, 13 months.

Of 29 industry-sponsored phase 1 interventional studies under Malaria, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 18. This study's 13 months is above that.

Counting every sponsor, half of 93 studies reached it within 13 months; a quarter within 7 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2016
First posted
Aug 9, 2016
StartActual
Nov 2016
Primary completionActual
Dec 2017
CompletionActual
Feb 2018
Last update
Oct 15, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02859350
Lead sponsor
Sanaria Inc.
Collaborators
Ifakara Health Institute, Swiss Tropical & Public Health Institute, Government of Equatorial Guinea, Marathon Oil Corporation, Noble Oil Services, La Paz Medical Center, Malabo, Equatorial Guinea
Responsible party
Sponsor
First posted
Aug 9, 2016
Start date
Nov 2016
Primary completion
Dec 2017
Completion
Feb 2018
Last update
Oct 15, 2018

Study contacts

Salim Abdulla, MD, PHD
study director · Ifakara Health Institute (IHI)

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion